Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials

References

• Cancer in Norway 2004 [Internet]. Cancer Registry of Norway. Oslo: Institute of Population-based Cancer Research; 2006. Available from http://www.cancerregistry.no
   Google Scholar
• Malvezzi M, Arfé A, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality prediction for the year 2011. Ann Oncol 2011;22:947–56.
   PubMed Web of Science ®Google Scholar
• Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 2000;355:1822.
   PubMed Web of Science ®Google Scholar
• Cheung KL. Endocrine therapy of breast cancer: An overview. Breast 2007;16:327–43.
   PubMedGoogle Scholar
• Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995;345:1265–70.
   PubMed Web of Science ®Google Scholar
• Grilli R, Minozzi S, Tinazzi A, Labianca R, Sheldon TA, Liberati A. Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. Ann Oncol 1998;9:365–74.
   PubMedGoogle Scholar
• Kingsmore D, Hole D, Gillis C. Why does specialist treatment of breast cancer improve survival? The role of surgical management. Br J Cancer 2004;90:1920–5.
   PubMed Web of Science ®Google Scholar
• Richards M, Sainsbury R, Kerr D. Inequalities in breast cancer care and outcome. Br J Cancer 1997;76:634–8.
   PubMedGoogle Scholar
• Guller U, Safford S, Pietrobon R, Heberer M, Oertli D, Jain NB. High hospital volume is associated with better outcomes for breast cancer surgery: Analysis of 233,247 patients. World J Surg 2005;2:994–9; Discussion 999–1000.
   Google Scholar
• Skinner KA, Helsper JT, Deapen D, Ye W, Sposto R. Breast cancer: Do specialists make a difference? Ann Surg Oncol 2003;10:606–15.
   PubMed Web of Science ®Google Scholar
• Stefoski Mikeljevic J, Haward RA, Johnston C, Sainsbury R, Forman D. Surgeon workload and survival from breast cancer. Br J Cancer 2003;89:487–91.
   PubMedGoogle Scholar
• Raabe NK, Kaaresen R, Fossaa SD. Hospital-related differences in breast cancer managment. Analysis of an unselected population-based series of 1353 radically operated patients. Breast Cancer Res Treat 1997;43:225–35.
   PubMedGoogle Scholar
• Harcourt KF, Hicks KL. Is there a relationship between case volume and survival in breast cancer? Am J Surg 2003;185: 407–10.
   PubMedGoogle Scholar
• Gundersen S, Hannisdal E, Søreide JA, Skarstein A, Varhaug JE. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: A randomized study. Breast Cancer Res Treat 1995;36:49–53.
   PubMedGoogle Scholar
• Söreide JA, Varhaug JA, Fjösne HE, Erikstein B, Jacobsen A-B, Skovlund E, . Adjuvant endocrine treatment (goserelin vs. tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. Eur J Surg Oncol 2002;28: 505–10.
   PubMed Web of Science ®Google Scholar
• Fjösne HE, Jacobsen A-B, Lundgren S. Adjuvant cyclic tamoxifen and megestrol acetate treatment in post-menopausal breast cancer patients – longterm follow-up. A prospective randomized national multicenter study. Eur J Surg Oncol 2007;34:6–12.
   PubMedGoogle Scholar
• Lundgren S, Jørgensen S, Kåresen R. Surgery for breast cancer patients in Norway 1990–95. Tidskr Nor Lægeforen 2001; 121:2688–93. Norwegian.
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Ingram DM, McEvoy SP, Byrne MJ, Fritschi L, Joseph DJ, Jamrozik K. Surgical caseload and outcomes for women with invasive breast cancer treated in Western Australia. Breast 2005;14:11–7.
   PubMedGoogle Scholar
• Johansen MA, Mayer DK, Hoover HC Jr. Obstacles to implementing cancer clinical trials. Semin Oncol Nurs 1991; 7:260–7.
   PubMedGoogle Scholar
• Lara PN Jr, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, . Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol 2005;23:9282–89.
   PubMed Web of Science ®Google Scholar
• Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Systematic review to determine whether participation in a trial influences outcome. Br Med J 2005;330:1175–9. Review.
   PubMed Web of Science ®Google Scholar
• Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review. Lancet 2004;363:263–70. Review.
   PubMed Web of Science ®Google Scholar
• EUSOMA. The requirements of a specialist breast unit. Eur J Cancer 2000;36:2288–93.
   PubMed Web of Science ®Google Scholar
• Raabe NK, Kaaresen R, Fosså SD. Analysis of adjuvant treatment in postmenopausal patients with stage II invasive breast carsinoma. A pattern of care study and quality assurance of 431 consecutive patients in Oslo. Acta Oncol 1997;36:255–60.
   PubMed Web of Science ®Google Scholar
• Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, . The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol 2007;25:2019–25.
   PubMedGoogle Scholar
• Basnett I, Gill M, Tobias JS. Variations in breast cancer management between a teaching and a non-teaching district. Eur J Cancer 1992;28A:1945–50.
   PubMedGoogle Scholar